Background: Botulinum toxin A is effective for treatment of idiopathic detrusor overactivity (IDO). The trigone is generally spared because of the theoretical risk of vesicoureteric reflux (VUR), although studies assessing injection sites are lacking.
Objective: Evaluate efficacy and safety of trigone-including versus trigone-sparing intradetrusor injections of abobotulinumtoxinA in patients with IDO.
Design, Setting, And Participants: Twenty-two patients from one centre were randomised to trigone-including or trigone-sparing injections.
Intervention: Injection of 500 U abobotulinumtoxinA diluted to 20ml into 20 trigone-including or trigone-sparing sites.
Measurements: The primary outcome measure was total overactive bladder symptom score (OABSS) at 6 wk. The OABSS questionnaire was completed at 0, 6, 12, and 26 wk. Baseline and postinjection urodynamic studies and micturating cystourethrograms were performed. Baseline values and subsequent time points were compared by t test. A mixed-effect model was used for repeated measures in time.
Results And Limitations: For symptom scores at baseline compared with scores at 6 wk postinjection, the mean total OABSS improved from 22.4 to 8.7 (p<0.001) in the trigone-including group compared with 22.7 to 13.4 (p<0.03) in the trigone-sparing group. The difference in mean change from baseline was 4.4 points in favour of the trigone-including group (p=0.03). The total OABSS at 12 and 26 wk and the urgency subscale scores at 6, 12, and 26 wk showed significant improvement in favour of the trigone-including group. Mean postvoid residual volumes and clean intermittent self-catheterisation rates between the two groups were similar. No patients developed VUR. Performing injections under general anaesthetic was a limitation, as tolerability under local anaesthetic was not assessed. A further limitation is the lack of a trigone-only arm.
Conclusions: Trigone-including injections are superior to trigone-sparing injections for the treatment of refractory IDO and did not cause VUR in this study.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.eururo.2011.10.043 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Urodynamic Changes Following Fewer Injection Sites of Intravesical Botulinum Toxin in Idiopathic Detrusor Overactivity: A Double-Blinded Prospective Randomized Clinical Trial.
Int Urogynecol J
January 2025
Department of Urology, Hasheminejad Kidney Center, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Introduction And Hypothesis: This study was aimed at evaluating the therapeutic effects of a modified intravesical botulinum toxin injection technique (fewer injection sites under local anesthesia), in comparison with the conventional technique for patients with idiopathic detrusor overactivity, considering the urodynamic parameters.
Methods: In this double-blinded randomized clinical trial, 78 adult females with idiopathic detrusor overactivity were divided into two groups: conventional and modified groups. In the conventional method, patients received intradetrusor botulinum toxin injection at 20 sites under general or spinal anesthesia in a trigone-sparing fashion.
The use of a percutaneous cystostomy tube as an adjunctive treatment option for dogs with idiopathic functional outflow tract obstruction.
J Vet Intern Med
December 2024
Schwarzman Animal Medical Center, Diagnostic and Interventional Radiology, 510 East 62nd Street, New York, New York 10065, USA.
Background: Functional outflow tract obstruction (FOO) remains a challenging disease to manage in male dogs. Cystostomy tubes have been used to relieve urethral obstruction while allowing time to achieve effective medical management, avoiding the need for emergency visits and repeat urinary catheterizations.
Objectives: To describe a series of dogs with FOO and categorize the most successful management strategies including medical management alone or with the support of cystostomy tubes for urinary diversion.
Assessing the Use of BotulinumtoxinA for Hyperactive Urinary Tract Dysfunction a Decade After Approval: General Versus Local Anesthesia for BotulinumtoxinA Detrusor Injection.
Toxins (Basel)
October 2024
Department of Urology, Charité-University Hospital Berlin, 12203 Berlin, Germany.
Article Synopsis
- OnabotulinumtoxinA detrusor injection (OnabotA DI) is a treatment for patients with overactive bladder issues that was approved 10 years ago, often performed under local anesthesia (LA) or general anesthesia (GA).
- In a study of 104 patients, those under LA reported higher anxiety and pain compared to those under GA, particularly during the first injection, but surprisingly still preferred LA despite these concerns.
- The findings highlighted a notable decrease in anxiety for repeat injections with LA, suggesting that familiarity with the procedure could ease patient anxiety over time, even though pain was significantly lower with GA.
Outcome of post-prostatectomy stress urinary incontinence surgery in men with preoperative idiopathic detrusor overactivity.
BJUI Compass
November 2024
Centre for Health, Performance and Wellbeing Anglia Ruskin University Cambridge UK.
Background: Urodynamic evidence of storage dysfunction such as detrusor overactivity (DO) and/or poor compliance are present in up to 30-40% of patients after Radical Prostatectomy (RP). However, the current optimal management of men with DO on preoperative urodynamics prior to male stress urinary incontinence (SUI) surgery is not known.
Methods: We performed a systematic search of the literature including articles on patients undergoing SUI surgery after prostatectomy with preoperative DO between January 2003 and May 2023 to ensure contemporaneous data was obtained.
Response to Treatment with Botulinum Neurotoxin A (BoNT-A) in Children and Adolescents with Neurogenic Lower Urinary Tract Dysfunction and Idiopathic Overactive Bladder: A Systematic Review and Meta-Analysis.
Toxins (Basel)
October 2024
Urology Clinic, Department of Surgery, Dentistry, Paediatrics and Gynaecology, University of Verona, Azienda Ospedaliera Universitaria Integrata di Verona, Piazzale Aristide Stefani 1, 37126 Verona, Italy.
Article Synopsis
- Botulinum neurotoxin A (BoNT-A) is being increasingly used to treat neurogenic lower urinary tract dysfunctions and overactive bladder in children and adolescents, which is a growing area in urology.
- A systematic review analyzed various studies from databases like PubMed and Scopus to evaluate BoNT-A's effectiveness in improving urinary incontinence and urodynamic parameters in this age group.
- Results showed that among 1521 patients, there was a significant improvement in urinary incontinence scores by about 75% within 3-6 months after treatment, with no major adverse effects reported.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!